Errata to the FDA Briefing Document

Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)

September 10-11, 2020

Note: Page numbers reflect the numbers at the bottom right of the page within the document

FDA Errata to Briefing Document

Page 1 "Oxyconting	Page 1 "Oxycontin" should read "OxyContin"		
Drug Utilization Review			
• Page 110	Tables 2-6 and 8 are included in the appendix; this is why only		
	Tables 1 and 7 appear in the body of the review.		
DEPI Review PMR Study 3051-1			
• Page 118	"6.14 Assessing Screen Changes" should read "6.14 ITS Analyses		
	with Additional Models"		
• Page 118	"6.15 Model Assessments" should read "6.15 Assessing Screen		
	Changes"		
• Page 118	"6.16 Comparators" should read "6.16 Model Assessments"		
• Page 118	"6.17 Summary Table of Published Literature Related to PMR		
	3051-1" should read "6.17 Comparators"		
• Page 118	Missing "6.18 Summary Table of Published Literature Related		
	to PMR 3051-1"		
• Page 160	"Figure 13 below" should read "Figure 12 below"		
• Page 161	"Figure 14 depicts" should read "Figure 13 depicts"		
• Page 162	"Figure 15 below" should read "Figure 14 below"		
• Page 163	"Figure 16, which uses" should read "Figure 15, which uses"		
• Page 164	"Figure 17 below" should read "Figure 16 below"		
• Page 165	"Figure 18 depicts" should read "Figure 17 depicts"		
• Page 167	"Figure 19-20" should read "Figure 18-19"		
• Page 169	"Figure 21-22" should read "Figure 20-21 "		
• Page 173	"Figure 23 (and table 22 in appendix 6.5)" should read "Figure 22		
	(and table 22 in appendix 6.5)"		
• Page 174	"Figure 24 (and table 23 in appendix 6.5)" should read "Figure 23		
	(and table 23 in appendix 6.5)"		
• Page 177	"Figure 25 below" should read "Figure 24 below"		
• Page 178	"Figure 26 below" should read "Figure 25 below"		
• Page 180	"Figure 27 (and table 28 in appendix 6.9)" should read "Figure 26		
	(and table 28 in appendix 6.9)"		
• Page 185	"Figures 28 and 29 show" should read "Figures 27 and 28 show"		

• Page 186	"(Figure 29)" should read "(Figure 28)"
• Page 191	"Figures 30-32 below" should read "Figures 29-31 below"
• Page 191	"Figure 30 below" should read "Figure 29 below"
• Page 193	"Figure 31 shows" should read "Figure 30 shows"
• Page 194	"Figure 32 below" should read "Figure 31 below"
• Page 198	"Figures 33-34" should read "Figures 32-33 "
• Page 201	"Figure 35 shows" should read "Figure 34 shows"
• Page 201	"(refer to figure 32 section 3.4.8)" should read "(refer to figure 31 section 3.4.8)"
• Page 209	"are shown in figures 37-39 below" should read "are shown in figures 36-38 below"
• Page 209	"In population-based analyses (Figure 37)" should read "In population-based analyses (Figure 36)"
• Page 210	"In utilization-based analyses (Figure 38)" should read "In utilization-based analyses (Figure 37)"
• Page 211	"Figure 39 below" should read "Figure 38 below"
• Page 213	"Figure 40 shows" should read "Figure 39 shows"
• Page 214	"Figure 41 shows" should read "Figure 40 shows"
• Page 218	Section 4.2.3, third sentence: "From the pre- to post-period, the percent of individuals endorsing abuse of OxyContin who reported they snorted the drug decreased from 55.2% to 33.4%, and the percent who reported injecting the drug decreased from 31.5% to 19.8%. These descriptive analyses did not formally test for statistical significance, but the estimate for the post-period did lie outside the 95% confidence interval for the pre-period estimate. In analyses looking only at those who reported abuse of original OxyContin in the pre-period or reformulated OxyContin in the post-period, the percent reporting abuse via snorting decreased from 57.3% to 27.3%, and from 30.9% to 25.4% for injection. By contrast, the percent of individuals endorsing ER morphine who reported snorting the drug increased from 22.4% to 28.1%, and the percent who reported injecting increased from 40.4% to 49.1%. For the smaller subset of sites contributing ≥1 assessment per quarter, the percentage of those abusing IR hydrocodone combination products who reported snorting decreased slightly from 17.2% to 14.4%, and the percent injecting remained very low, decreasing from 1.6% to 0.2%. The results from the larger set of sites contributing ≥1 assessment/year were qualitatively different, and showed a small increase in proportion of IR hydrocodone cases via injection reported (Figure 89, appendix 6.11)."

• Page 315	"From the pre- to post-period, the percent of individuals endorsing abuse of OxyContin who reported they snorted the drug decreased from 55.9% to 32.2%, and the percent who reported injecting the drug decreased from 34.8% to 22.3%. These descriptive analyses did not formally test for statistical significance, but the estimate for the post-period did lie outside the 95% confidence interval for the pre-period estimate. In analyses looking only at those who reported abuse of original OxyContin in the pre-period or reformulated OxyContin in the post- period, the percent reporting abuse via snorting decreased from 55.9% to 25.8%, and from 34.8% to 18.8% for injection. By contrast, the percent of individuals endorsing ER morphine who reported snorting the drug changed only slightly from 33.2% to 32.1%, and the percent who reported injecting changed slightly from 54.4% to 53.6%. For the smaller subset of sites contributing ≥1 assessment per quarter, the percentage of those abusing IR hydrocodone combination products who reported snorting increased slightly from 14.8% to 17.9%, and the percent injecting remained very low, decreasing from 1.6% to 0.8%. The results from the larger set of sites contributing ≥1 assessment/year were qualitatively different, and showed a small increase in proportion of IR hydrocodone cases via injection (Figure 89, appendix 6.11)." Title for Table 39: "AIC model fit statistic values for changes in overall abuse for
	OxyContin relative to primary comparators, -2y/4y" should read
	"AIC model fit statistic values for changes in non-oral abuse for OxyContin relative to primary comparators, -2y/4y"
DBVII Memorandum	Oxycontin relative to primary comparators, 2y/+y
• Page 718	There is no Figure 4.
• Page 703	The following footnote moved to the next page: "†Rate ratio is defined by a ratio between rates in pre- and post-reformulation period for a single opioid. RORR is a ratio between two rate ratios (one for OxyContin; the other for a comparator) obtained from difference-in-differences type of analysis. See Section 4 for details."
• Page 711	"Figure 3 shows" should read "Figure 1 shows"
• Page 724	"Table 4 presents" should read "Table 5 presents"
• Page 724	"Table 5 presents" should read "Table 6 presents"
• Page 724	"Table 5 only highlights" should read "Table 6 only highlights"
• Page 725	"Table 6 presents" should read "Table 7 presents"
• Page 725	"Table 6 depicts" should read "Table 7 depicts"
• Page 725	"(denoted by CIS in Table 6)" should read "(denoted by CIS in Table 7)"
• Page 725	"(denoted by IS in Table 6)" should read "(denoted by IS in Table 7)"

• Page 726 "Table 7 presents" should read "Table 8 presents"